Loading...
Market
Story
Pfizer's Ibrance Extends Survival by 15 Months in Breast Cancer Patients
Dec 12, 2024, 03:07 PM
Pfizer Inc. has announced that its drug Ibrance, which generates annual sales of $4.3 billion, has shown efficacy in extending median progression-free survival by over 15 months in a Phase 3 study for patients with HR+, HER2+ metastatic breast cancer. This development could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis. The study, known as PATINA, involved combining Ibrance with standard-of-care therapies, marking a potential expansion of its use to a new patient population that represents 10% of breast cancer cases.
View original story
Similar markets
Verzenio (abemaciclib) • 25%
Kisqali (ribociclib) • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
AWS • 25%
Deloitte • 25%
Microsoft • 25%
Nvidia • 25%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
Merck • 25%
Bristol-Myers Squibb • 25%
Roche • 25%
Other • 25%